A Review of Novel Anticoagulants and Management of Bleeding Complications in Patients Prescribed Novel Anticoagulants: What You Need to Know

Document Type

Presentation

Loading...

Media is loading
 

Publication Date

11-12-2013

Comments

ACPE # 0079-9999-13-127-H01-P

Expiration Date: 11/12/2015

Knowledge Based Activity; eligible for 1 Contact Hour

The following knowledge-based CPE programs have been developed in conjunction with The Jefferson School of Population Health and Department of Pharmacy of Thomas Jefferson University Hospital. The programs are free to all Jefferson pharmacists.

Method & Format

Each online program consists of audio with slides. After viewing the online course, contact Melissa Horowitz at Melissa.horowitz@jefferson.edu to receive the post-test and activity evaluation.

A minimum score of 70% is required on the test for credit to be awarded. The estimated time to complete this activity is 1 hour. Participants who successfully complete will be awarded 1.00 hours of continuing pharmacy education credit (.100 CEUs).

Participants should claim continuing education credit for this internet-based educational activity only if they have not claimed credit for the live activity.

Target Audience

This continuing pharmacy education activity was planned to meet the needs of Jefferson pharmacists in a variety of practice settings, including large and small health systems, managed-care organizations, and academia.

System Requirements

Please ensure that the computer you plan to use meets the following requirements:

  • Operating System: Microsoft Windows, Apple Mac OS X, Apple iOS (iPad)
  • Supported Browsers: Google Chrome (recommended), Mozilla Firefox and Apple Safari
  • Internet Connection: Broadband recommended

Please contact the ACPE administrator at (215) 955-9817 with any questions pertaining to these programs.

Abstract

Objectives

  • Explain the mechanisms of action, pharmacokinetics, safety concerns, monitoring parameters and FDA approved indications for each new oral anticoagulant
  • Review recommended time to hold novel anticoagulants prior to invasive procedures/emergency surgery
  • Demonstrate knowledge of reversal strategies for the management of emergent bleeding complications of newly approved agents
  • Evaluate current literature available on the use of prothrombin complex concentrate to reverse bleeding from rivaroxaban and dabigatran.

This document is currently not available here.

Share

COinS